Bate A (2000) "Validating" automated signal detection methods used in spontaneous reporting systems. In: 16th International Conference on Pharmacoepidemiology. Barcelona.

Bate A, et al. (1998a) A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol 54: 315-21.

Bate A, et al. (1998b) Identifying and quantifying signals automatically. Pharmacoepidemiology and Drug Safety 7 (Suppl 2).

Bate A, Lindquist M, Orre R, Meyboom R, Edwards R (2000) Automated classification of signals as group effects or drug specific on the WHO database. In: 8th Annual Meeting European Society of Pharmacovigi-lance. Verona: Elsevier.

Bowdler J (1997) Effective Communications in Pharma-covigilance, Vol. 1, 1st edn. Birmingham, England: W. Lake Ltd.

CIOMS (1995) Harmonization of Data Fields for Electronic Transmission of Case-Report Information Internationally. Geneva: CIOMS.

Edwards IR (1997) Pharmacological basis for adverse drug reactions. In: Speight T, Holford N, eds., Avery's Drug Treatment. Auckland: Adis International Ltd, pp. 261-99.

Edwards IR (1999) Spontaneous reporting—of what? Clinical concerns about drugs. Br J Clin Pharmacol 48: 138-41.

Edwards IR (2000) The accelerating need for pharma-covigilance. J R Coll Phys Lond 34(1): 48-51.

Edwards IR, Biriell C (1994) Harmonisation in pharma-covigilance. Drug Safety 10: 93-102.

Edwards IR, Fucik H (1996) Impact and credibility of the WHO adverse reaction signals. Drug Inf J 30(2): 461 -4.

Edwards IR, Hugman B (1997) The challenge of effectively communicating risk-benefit information. Drug Safety 17(4): 216-27.

Edwards IR, Wiholm B-E, Martinez C (1996) Concepts in risk-benefit assessment. Drug Safety 15(1): 1-7.

Edwards IR, et al. (1990) Quality criteria for early signals of possible adverse drug reactions. Lancet 336: 156-8.

Edwards IR, et al. (1993a) Proposed improvement to the WHO Adverse Reaction Terminology (WHO-ART). Pharmacoepidemiology and Drug Safety 2: 177-84.

Edwards IR, et al. (1993b) Towards a new adverse event dictionary. Pharmacoepidemiology and Drug Safety 2: 175-6.

Edwards IR et al. (2000) Understanding and communication of key concepts in therapeutics. In: Moments of Truth—Communicating Drug Safety. Verona: Elsevier.

Farah MH (1998) Consumer protection and herbal remedies. WHO Drug Information 12(3): 141.

Farah MH. (2000a) Key issues in herbal pharmaco-vigilance. Adverse Drug Reactions J 2(2): 105-9.

Farah MH, et al. (2000b) International monitoring of adverse health effects associated with herbal medicines. Pharmacoepidemiology and Drug Safety 9: 10512.

Lindquist M, Edwards IR (1993) Adverse drug reaction reporting in Europe: some problems of comparison. Int J Risk Safety Med 4: 35-46.

Lindquist M, Edwards IR (1997) Risks of non-sedating antihistamines. Lancet 349: 1322.

Lindquist M (1990) Uses and limitations of a global reporting pool. In: Meeting on Methods for the Detection and Study of Unwanted Drug Effect. Kiel, Germany, 26-29 Nov.

Lindquist M (1998) The WHO Programme for International Drug Monitoring: the present and future. In: Mitchard M, ed., Electronic Communication Technologies. pp. 527-49.

Lindquist M (2000) Signal detection using the WHO international database. In: 8th Annual Meeting European Society of Pharmacovigilance. Verona: Elsevier.

Lindquist M, et al. (1994) Pharmacovigilance information on an old drug—an international study of spontaneous reports on Digoxin. Drug Investigation 8: 73-80.

Lindquist M, et al. (1996) Omeprazole and visual disorders: seeing alternatives. Pharmacoepidemiology and Drug Safety 5: 27-32.

Lindquist M, et al. (1997) How does cystitis affect a comparative risk profile of tiaprofenic acid with other non-steroidal antiinflammatory drugs? An international study based on spontaneous reports and drug usage data. Pharmacol Toxicol 80: 211-17.

Lindquist M, et al. (1999) From association to alert—a revised approach to international signal analysis. Pharmacoepidemiology and Drug Safety 8: S15 -S25.

Lindquist M, Farah MH, Edwards R (2000) Monitoring of herbal medicines. In: Clinical Pharmacology and Therapeutics. Florence: Blackwell.

Meyboom RHB (2000) The case for good pharmaco-vigilance practice. Pharmacoepidemiology and Drug Safety 9: 335-6.

Meyboom RHB, Lindquist M, Flygare AK, Biriell C, Edwards IR (2000a) Should therapeutic ineffectiveness be reported as an adverse drug reaction? In: 8th Annual Meeting European Society of Pharmacovigi-lance. Verona: Elsevier.

Meyboom RHB, Lindquist M, Flygare A-K, Biriell C, Edwards RI (2000b) The value of reporting therapeutic ineffectiveness as an adverse drug reaction. Drug Safety 23(2): 95-99.

Mills A, Edwards IR (1999) Venous thromboembolism and the pill. Human Reproduction 14(1): 7-10.

Olsson S, ed. (1997) National Pharmacovigilance Systems. Uppsala: Uppsala Monitoring Centre.

Orre R, et al. (2000) Bayesian neural networks with confidence estimations applied to data mining. Computational Statistics and Data Analysis 34(8): 473-93.

WHO and Uppsala Monitoring Centre (2000) Safety Monitoring of Medicinal Products. Uppsala: WHO and Uppsala Monitoring Centre.

Drug Free Life

Drug Free Life

How To Beat Drugs And Be On Your Way To Full Recovery. In this book, you will learn all about: Background Info On Drugs, Psychological Treatments Statistics, Rehab, Hypnosis and Much MORE.

Get My Free Ebook

Post a comment